BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Federal Trade Commission
Express Scripts

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020705

« Back to Dashboard
NDA 020705 describes RESCRIPTOR, which is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the RESCRIPTOR profile page.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. Two suppliers are listed for this compound. Additional details are available on the delavirdine mesylate profile page.

Summary for 020705

Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Pharmacology for NDA: 020705

Medical Subject Heading (MeSH) Categories for 020705

Suppliers and Packaging for NDA: 020705

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
delavirdine mesylate
TABLET;ORAL 020705 NDA KAISER FOUNDATION HOSPITALS 0179-0096 0179-0096-70 30 TABLET in 1 BOX, UNIT-DOSE (0179-0096-70)
delavirdine mesylate
TABLET;ORAL 020705 NDA ViiV Healthcare Company 49702-209 49702-209-24 360 TABLET in 1 BOTTLE (49702-209-24)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Apr 4, 1997TE:RLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength200MG
Approval Date:Jul 14, 1999TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jun 7, 2019Product Flag?Substance Flag?Delist Request?

Expired Orange Book Patents for NDA: 020705

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare
delavirdine mesylate
TABLET;ORAL020705-001Apr 4, 1997► Subscribe► Subscribe
Viiv Hlthcare
delavirdine mesylate
TABLET;ORAL020705-002Jul 14, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cantor Fitzgerald
Daiichi Sankyo
Argus Health
Queensland Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus